# Design Therapeutics, Inc. (DSGN)

> Source: Nexqual · https://nexqual.com/DSGN · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Design Therapeutics, Inc. (DSGN), nexqual.com/DSGN" · informational, not investment advice.

**Price:** USD 10.49 (-2.24% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 10.73 · day 10.44–10.85 · 52w 5.71–17.25 · market cap $656M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $0K, net income -$70.8M, free cash flow -$55.1M (SEC filings).
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 21.71 (range 20–26).
- Total return with dividends: 1Y +84.0% vs S&P 500 +14.9%; 5Y -29.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.35, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0K | $0K | $0K |
| Operating income | -$35.8M | -$67.6M | -$78.2M | -$62.4M | -$79.5M | -$79.4M |
| Net income | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M | -$70.8M |
| EPS (diluted) | -$0.77 | -$1.14 | -$1.19 | -$0.88 | -$1.22 | — |
| Free cash flow | -$30.9M | -$52.2M | -$58.8M | -$43.4M | -$54.6M | -$55.1M |
| Cash + short-term investments | $384M | $330M | $282M | $246M | $220M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 3.3x · FCF yield -8.40% · Earnings yield -10.78%

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 21.71 (low 20, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | Wells Fargo | Initiated | Overweight | $26 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +84.0% | -29.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +84.4% | -6.6% |
| Volatility (annualized) | 74.0% | 97.5% |
| Max drawdown | -39.0% (Aug 2026→Oct 2026) | -91.9% (Aug 2022→Nov 2023) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/DSGN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in DSGN's own 10-K filed 2026-03-09 (https://www.sec.gov/Archives/edgar/data/1807120/000119312526098491/dsgn-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Eli Lilly (LLY) | "We will also compete more generally with other companies developing alternative scientific and technological approaches to modulate individual genes, including other companies working to develop nuclease-based gene editi…" |

## Company outlook (8-K filed 2026-08-03)

- "In addition, modifications include specifying endogenous blood FXN protein percent change from baseline as the primary efficacy endpoint and exploring a dose level above 1 mpk. • Next Steps and Expected Milestones: Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027."
- "Design anticipates reporting data from this study in 2027. • Fuchs Endothelial Corneal Dystrophy (FECD): A Phase 2 biomarker trial of DT-168 is ongoing to evaluate safety, tolerability and corneal endothelium biomarkers in FECD patients who are scheduled for corneal transplant surgery."
- "Data is now expected in 2027 due to a delay in the anticipated supply of DT-168 blow-fill-seal eye droppers. • Huntington's disease (HD): Design continues to advance preclinical characterization of several candidate molecules for its Huntington's disease program."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.35 | $-0.36 | -3.4% | $0 | 8 |
| Next quarter (ends 2026-12-31) | $-0.39 | $-0.37 | +5.5% | $0 | 8 |
| Current fiscal year (ends 2026-12-31) | $-1.35 | $-1.36 | -0.9% | $0 | 8 |
| Next fiscal year (ends 2027-12-31) | $-1.62 | $-1.64 | -1.0% | $0 | 8 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±33.1%; last 8 reports averaged ±7.2%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 143.7% | ±33.1% |
| 2026-12-18 | 56 | 93.9% | ±32.9% |
| 2027-01-15 | 84 | 89.0% | ±49.6% |
| 2027-04-16 | 175 | 84.3% | ±47.7% |